Document Type : Review Paper

Authors

1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Mosul, Mosul, Iraq

2 Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq

Abstract

Background: Chronic inflammation is responsible for low insulin sensitivity, making obesity a major risk factor for developing insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. Increased expression of inflammatory cytokines activates several signaling pathways, consequently leading to the accumulation of fats in adipocytes and contributing to the pathogenesis of insulin resistance. Aim: The review aimed to provide an overview of the potential molecular correlation between the insulin signaling pathway and the inflammatory process in addition to their linkage to the development of insulin resistance and other metabolic diseases, with an exploration of the possibility of using drugs that target inflammation in the management of diabetes. Results: Based on the obtained data from the latest literature, the source of cytokines in insulin-resistant states is the insulin targets themselves including the adipose tissue and liver, but to a greater extent the activated macrophages. Prolonged inflammation in these tissues may result in systemic insulin resistance via endocrine signaling and localized insulin resistance by paracrine/autocrine cytokine signaling. Conclusion: Inflammation is involved in the pathogenesis of insulin resistance and diabetes type 2, consequently, in the management of insulin resistance, anti-inflammatory agents may benefit, and the risk assessment may benefit from the use of inflammatory biomarkers in such disorders.

Highlights

  • Inflammation negatively affects the action of insulin
  • Insulin resistance causes a loss of insulin actions at baseline levels
  • Obesity is a condition of low-grade inflammation that induces insulin resistance

Keywords

Main Subjects

  1. Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes, metabolic syndrome and obesity: targets and therapy. 2020; 13: 3611-3616.
  2. Payankaulam S, Raicu A-M, Arnosti DN. Transcriptional Regulation of INSR, the Insulin Receptor Gene. Genes. 2019; 10(12): 984.
  3. Mayer JP, Zhang F, DiMarchi RD. Insulin structure and function. Biopolymers. 2007; 88(5): 687-713.
  4. Ünal D. Insulin hormone: Mechanism and effects on the body and relationship with central nervous system. Dicle Medical Journal / Dicle Tip Dergisi. 2012; 39(2): 310-315.
  5. Ahmed G, Abed M, Alassaf F. An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients. Iraqi Journal of Pharmacy. 2023; 20(1): 65-71.
  6. Hua Q. Insulin: a small protein with a long journey. Protein & Cell. 2010; 1(6): 537-551.
  7. Lee S-H, Park S-Y, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes & Metabolism Journal. 2022; 46(1): 15-37.
  8. Rabiee A, Krüger M, Ardenkjær-Larsen J, Kahn CR, Emanuelli B. Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action. Cellular signalling. 2018; 47: 1-15.
  9. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nature Reviews Molecular Cell Biology. 2006; 7(2): 85-96.
  10. Titchenell PM, Chu Q, Monks BR, Birnbaum MJ. Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nature communications. 2015; 6: 7078.
  11. Sylow L, Tokarz VL, Richter EA, Klip A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metabolism. 2021; 33(4): 758-780.
  12. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: Implications for diabetes. Molecular and Cellular Endocrinology. 2009; 302(2): 128-139.
  13. Arkun Y. Dynamic Modeling and Analysis of the Cross-Talk between Insulin/AKT and MAPK/ERK Signaling Pathways. PLOS ONE. 2016; 11(3): e0149684.
  14. Usui I, Imamura T, Huang J, Satoh H, Olefsky JM. Cdc42 Is a Rho GTPase Family Member That Can Mediate Insulin Signaling to Glucose Transport in 3T3-L1 Adipocytes. Journal of Biological Chemistry. 2003; 278(16): 13765-13774.
  15. Reid J, Macdougall AI, Andrews MM. Aspirin and Diabetes Mellitus. British medical journal. 1957; 2(5053): 1071-1074.
  16. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ. Science. 2001; 293(5535): 1673-1677.
  17. Jasim MHM, Abed MN, Qazzaz ME, Alfahad M, Alassaf FA. Aspirin-aromatic amino acid conjugates as selective Cox-2 inhibitors: A docking study. Tropical Journal of Pharmaceutical Research. 2021; 30(3): 579-583.
  18. Al-dabbagh BMA, Abed MN, Mahmood NM, Jasim AAFMH, Alfahad M, and Thanoon IA-J. Anti-inflammatory, antioxidant and hepatoprotective potential of milk thistle in albino rats. Latin American journal of pharmacy. 2022; 14(9): 1832-1841.
  19. Kim J, Lee J. Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions. Annals of pediatric endocrinology & metabolism. 2021; 26(1): 1-13.
  20. Alemzadeh R, Kichler J. Gender differences in the association of insulin resistance and high-sensitivity c-reactive protein in obese adolescents. Journal of diabetes and metabolic disorders. 2014; 13(1): 35.
  21. Kanda H. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation. 2006; 116(6): 1494-1505.
  22. Himsworth H. Diabetes Mellitus: Its differentiation into insulin-sensitive and insulin-insensitive types. International Journal of Epidemiology. 2013; 42(6): 1594-1598.
  23. Alassaf FA, Jasim MHM, Alfahad M, Qazzaz ME, Abed MN, Thanoon IA-J. Effects of bee propolis on FBG, HbA1c, and insulin resistance in healthy volunteers. Turkish Journal of Pharmaceutical Sciences. 2021; 18(4): 405-409.
  24. Lebovitz H. Insulin resistance: definition and consequences. Experimental and Clinical Endocrinology & Diabetes. 2001; 109(Suppl 2): S135-S148.
  25. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diabetes and Vascular Disease Research. 2019; 16(2): 118-127.
  26. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. Journal of biomedicine & biotechnology. 2010; 2010: 476279.
  27. Lee S, Lynn EG, Kim J-A, Quon MJ. Protein kinase C-zeta phosphorylates insulin receptor substrate-1, -3, and -4 but not -2: isoform specific determinants of specificity in insulin signaling. Endocrinology. 2008; 149(5): 2451-2458.
  28. da Silva Rosa SC, Nayak N, Caymo AM, Gordon JW. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue. Physiological reports. 2020; 8(19): e14607.
  29. Gaggini M, Morelli M, Buzzigoli E, DeFronzo R, Bugianesi E, Gastaldelli A. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. Nutrients. 2013; 5(5): 1544-1560.
  30. Santoleri D, Titchenell PM. Resolving the Paradox of Hepatic Insulin Resistance. Cellular and molecular gastroenterology and hepatology. 2019; 7(2): 447-456.
  31. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006; 127(1): 125-137.
  32. Kim K, Ryu D, Dongiovanni P, et al. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Gastroenterology. 2017; 153(6): 1568-1580.e10.
  33. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell metabolism. 2006; 4(2): 107-110.
  34. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (New York, NY). 1993; 259(5091): 87-91.
  35. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994; 43(11): 1271-1278.
  36. Kumar DP, Koka S, Li C, Rajagopal S. Inflammatory Mediators in Obesity. Mediators of Inflammation. 2019; 2019: 1-2.
  37. Popko K, Gorska E, Stelmaszczyk-Emmel A, et al. Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects. European Journal of Medical Research. 2010; 15(S2): 120.
  38. Shoelson SE. Inflammation and insulin resistance. Journal of Clinical Investigation. 2006; 116(7): 1793-1801.
  39. Akira S, Uematsu S, Takeuchi O. Pathogen Recognition and Innate Immunity. Cell. 2006; 124(4): 783-801.
  40. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomedicine & Pharmacotherapy. 2018; 107: 306-328.
  41. Lin Y, Berg AH, Iyengar P, et al. The Hyperglycemia-induced Inflammatory Response in Adipocytes. Journal of Biological Chemistry. 2005; 280(6): 4617-4626.
  42. Alfahad M, Qazzaz ME, Abed MN, Alassaf FA, Jasim MHM. Comparison of Anti-oxidant activity of different brands of esomeprazole available in Iraqi pharmacies. Systematic Reviews in Pharmacy. 2020; 11(5): 330-334.
  43. Abed MN, Alassaf FA, Jasim MHM, Alfahad M, Qazzaz ME. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole. Pharmacology. 2020; 105(11-12): 645-651.
  44. Guebre-Egziabher F, Alix PM, Koppe L, et al. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function. Biochimie. 2013; 95(11): 1971-1979.
  45. Feng J, Lu S, Ou B, et al. The Role of JNk Signaling Pathway in Obesity-Driven Insulin Resistance. Diabetes, metabolic syndrome and obesity: targets and therapy. 2020; 13: 1399-1406.
  46. Arkan MC, Hevener AL, Greten FR, et al. IKK-β links inflammation to obesity-induced insulin resistance. Nature Medicine. 2005; 11(2): 191-198.
  47. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Letters. 2008; 582(1): 97-105.
  48. Sokolowska E, Blachnio-Zabielska A. The Role of Ceramides in Insulin Resistance. Frontiers in Endocrinology. 2019; 10: 577.
  49. Powell DJ, Hajduch E, Kular G, Hundal HS. Ceramide Disables 3-Phosphoinositide Binding to the Pleckstrin Homology Domain of Protein Kinase B (PKB)/Akt by a PKCζ-Dependent Mechanism. Molecular and Cellular Biology. 2003; 23(21): 7794-7808.
  50. Galadari S, Rahman A, Pallichankandy S, Galadari A, Thayyullathil F. Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids in Health and Disease. 2013; 12(1): 98.
  51. Adams CJ, Kopp MC, Larburu N, Nowak PR, Ali MMU. Structure and molecular mechanism of ER stress signaling by the unfolded protein response signal activator IRE1. Frontiers in Molecular Biosciences. 2019; 6(MAR).
  52. Flamment M, Hajduch E, Ferré P, Foufelle F. New insights into ER stress-induced insulin resistance. Trends in Endocrinology & Metabolism. 2012; 23(8): 381-390.
  53. Brown M, Dainty S, Strudwick N, et al. Endoplasmic reticulum stress causes insulin resistance by inhibiting delivery of newly synthesized insulin receptors to the cell surface. Molecular biology of the cell. 2020; 31(23): 2597-2629.
  54. Zatterale F, Longo M, Naderi J, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Frontiers in physiology. 2019; 10: 1607.
  55. Longo M, Zatterale F, Naderi J, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. International Journal of Molecular Sciences. 2019; 20(9): 2358.
  56. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. The Journal of Clinical Endocrinology & Metabolism. 2008; 93(11):57-63.
  57. Fujisaka S. The role of adipose tissue M1/M2 macrophages in type 2 diabetes mellitus. Diabetology International. 2021; 12(1): 74-79.
  58. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology. 2004; 25(12): 677-686.
  59. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. Journal of Interferon & Cytokine Research. 2009; 29(6): 313-326.
  60. Alfadul H, Sabico S, Al-Daghri NM. The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis. Frontiers in Endocrinology. 2022; 13.
  61. Draoui N, de Zeeuw P, Carmeliet P. Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism. Open Biology. 2017; 7(12): 170219.
  62. Herold J, Kalucka J. Angiogenesis in Adipose Tissue: The Interplay Between Adipose and Endothelial Cells. Frontiers in Physiology. 2021; 11.
  63. Qureshi K. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2007; 13(26): 3540.
  64. Bertola A, Bonnafous S, Anty R, et al. Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients. PLOS ONE. 2010; 5(10): e13577.
  65. Jager J, Aparicio‐Vergara M, Aouadi M. Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells. Journal of Internal Medicine. 2016; 280(2): 209-220.
  66. Freitas-Lopes M, Mafra K, David B, Carvalho-Gontijo R, Menezes G. Differential Location and Distribution of Hepatic Immune Cells. Cells. 2017; 6(4): 48.
  67. Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. In: Comprehensive Physiology. Wiley; 2020:785-809.
  68. Deans KA, Sattar N. “Anti-Inflammatory” Drugs and Their Effects on Type 2 Diabetes. Diabetes Technology & Therapeutics. 2006; 8(1): 18-27.
  69. Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease. Circulation. 2004; 109(18): 2197-2202.
  70. Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes & Metabolism. 2004; 30(6): 487-496.
  71. Bai B, Chen H. Metformin: A Novel Weapon Against Inflammation. Frontiers in Pharmacology. 2021; 12: 622262.
  72. Ceriello A. Thiazolidinediones as anti‐inflammatory and anti‐atherogenic agents. Diabetes/Metabolism Research and Reviews. 2008; 24(1): 14-26.
  73. Helmersson J, Vessby B, Larsson A, Basu S. Association of Type 2 Diabetes With Cyclooxygenase-Mediated Inflammation and Oxidative Stress in an Elderly Population. Circulation. 2004; 109(14): 1729-1734.